Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics Previous close 206.00
Open 204.50
Day range 201.30 205.10
52-week range 197.45 289.50
Off day high −0.24%
Off 52-week high −29.33%
Volume 324.45K
Avg. volume (3M) 243.02K
Market cap 39.01B
EPS (TTM) 11.32
Forward P/E 14.82
P/E ratio (TTM) 18.07
Dividend yield 0.71% (1.45)
Beta (5Y) —
Shares outstanding 190.66M
Short interest —
Earnings date Jul 30, 2026
Analyst target —
Profit margin —
No recent coverage in the 4Search index.
From articles in the 4Search news index.
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders, inflammatory disorders, and oncology.
From Wikipedia , CC BY-SA 4.0
Earnings
Next report: Thu, Jul 30, 2026
Not eligible for Gainers, Losers, Most active (U.S. stocks worth $2 billion or more only).
Not eligible for Small-cap gainers, Aggressive small caps (U.S. stocks worth under $2 billion only).
Not eligible for Growth tech (U.S. technology stocks only).
Not eligible for Undervalued large caps (U.S. stocks worth $10 billion or more only).
A day counts when it ranked in the top 25 of a list. Tracked since Oct 10, 2026.
Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use .